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 VACCINATION PLANNING IN ITALY: INCREASING VACCINES WHILE REDUCING COVERAGE? 
Vaccination protects both individuals and the community, reducing the risk of transmission and 
circulation of pathogens and thus preventing many diseases. Although vaccines may be potentially 
very cost-effective, the most recent are very expensive indeed [1]. 
Italy has a strong tradition in public health and vaccination planning, although the regionalization of 
the Italian National Health Service led to a decade of planning blight [2]. However a national vaccine 
plan (NVP) was approved in 2012 [3] and the new agreement (for the period 2016-2018) is awaiting 
final approval from the Ministry of Treasury [4]. 
Unexpectedly, the forthcoming NVP raised a fierce debate among Italian experts [5]. In an attempt to 
assess critically whether this debate was justified, we consider the main contents of the document and 
discuss its potential implications, mainly from an economic perspective. 
The new NVP 
In line with the (much shorter) previous plan, the general objective of the new NVP is the 
harmonization of regional vaccination strategies across Italy. Then, in the light of the generalized 
decreasing coverage for ‘historical’ vaccinations and the increasing risk factors due to immigration, 
several specific goals are stated, such as the preservation of polio-free status and the elimination of 
measles and rubella. 
The new NVP reaffirms the paradigm of health technology assessment (HTA) as the most suitable and 
transparent approach for decision makers to inform the introduction of new vaccinations. The main 
novelty is the inclusion of five new vaccination cycles in the national calendar: rotavirus, 
meningococcal B and HPV male extension, for youth population; anti-pneumococcal (PCV13 followed 
by PPV23) and anti-herpes zoster vaccines, for older adults. 
Intermediate vaccination targets aiming for the ‘gold standard’ of 95% coverage for each vaccination 
schedule are set, and as yet unspecified sanctions are envisaged for regions that do not achieve them. 
The yearly cost of vaccines at full coverage is estimated at €620 million (3.4% of total public 
pharmaceutical expenditure). 
Policy Implications 
The forthcoming NVP includes some elements of novelty, although with arguably scant evidence to 
support the most important innovations. HTA is still claimed to be a crucial tool for supporting the 
introduction of a new treatment, however there is no sign of it to justify the inclusion of the five new 
vaccinations. In particular, an epidemiological evaluation of the burden of preventable diseases in Italy 
would have been very useful to support the most controversial new vaccines, i.e. rotavirus for infants 
and herpes zoster for elderly people. We may have expected that the decreasing coverage for 
traditional vaccinations in infants would have led to reverse this trend as an urgent priority before 
 adding two further vaccination programmes for older adults. Investment in national computerized 
information registries would have been welcomed by all experts, since their piecemeal and uneven 
regional distribution is a well recognized obstacle to monitoring national coverage rates accurately [6], 
as the NVP acknowledges itself. 
Focusing on the economic implications of new vaccinations, the NVP foresees a doubling of vaccine 
spending according to the current prices in the (unlikely) situation of ideal coverage for all vaccinations. 
However, this forecast does not address the potential for price reductions as a result of competitive 
regional tenders [7]. As recently underlined by the national Antitrust Authority (Autorità Garante della 
Concorrenza e del Mercato, AGCM) [8], potential competition may be exploited further for traditional 
vaccinations, owing to new multivalent vaccines being marketed (two hexavalent for diphtheria-
hepatitisB-pertussis-polio-tetanus-haemophilus influenza b and two quadrivalent for measles-rubella-
parotitis-varicella), for HPV and PCV vaccinations, although with very uneven results for the two last 
ones so far - impressive for HPV [9] and negligible for PCV [2]. While the male extension for HPV could 
contribute to a further decrease of the prices awarded in regional tenders (€28.60 per dose [10] the 
lowest at present), the combined schedule of PCV13 and PPV23 foreseen for the extension of 
pneumococcal vaccination to older adults will preclude any kind of price competition in practice, although 
the difference between the two vaccines is less relevant for this target population [11,12]. There is little 
potential competition for herpes zoster and meningococcal vaccines, since only one manufacturer 
markets them, while two vaccines are available against rotavirus. 
Comment 
Public health experts are expected to advise decision makers on whether to adopt new public health 
interventions such as vaccinations. However, their advice should be strongly evidence based, 
particularly in the context of requests for universal coverage. When the advice is encouraging, a second 
question that health authorities should address is whether the vaccination is economically worthwhile. 
Even though vaccination is generally perceived as a cost-effective strategy, a thorough systematic 
assessment of the new costly vaccines is a priority in this period of economic difficulties and limited 
public expenditure. Rather than seeking support in simulated economic models, a more appropriate 
economic approach to make vaccines that have adequate evidence of effectiveness more sustainable 
may be to recur to competitive tenders whenever at least two vaccines are available as alternatives 
and choose the cheapest [7]. If health authorities do not consider these vaccines fully equivalent, a 
‘quality score’ could be added in tender clauses so as not to consider only the best price offered. Since 
any manufacturer tries to stress the difference between its product and the ‘competitor’, the crucial 
issue is where to ‘draw the line’ of substantial equivalence between similar vaccines for tendering. 
To conclude, we contend that health authorities striving to achieve sustainable prices through 
competitive tendering are very likely to sustain an acceptable cost-effectiveness ratio. Although this 
 strategy may not always maximize individual efficacy in the short term, we believe it will warrant the 
economic sustainability of vaccinations for society in the long run. If competition between vaccine 
manufacturers were exploited to the full, there may be also less scope for ‘outcries for conflicts of 
interest’ among experts [5], which can undermine the credibility of vaccinations among the public 
when amplified in the mass media. 
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